Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

NCT03573882 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
179
Enrollment
INDUSTRY
Sponsor class

Stopped Emerging clinical data evaluated by Pfizer and shared with regulatory authorities indicates that the risk profile of voxelotor in people with SCD exceeds the benefits observed in previously generated global research and requires further assessment.

Conditions

Interventions

Sponsor

Pfizer